Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-03-0538PMID 15073109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of low dose tamoxifen on normal breast tissue from premenopausal women.

  2003cited by this paper
• CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat and human liver microsomes

  2003cited by this paper
• A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.

  2003influential reference
• Overview of the main outcomes in breast-cancer prevention trials.

  2003cited by this paper
• Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

  2003cited by this paper
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003cited by this paper
• Tamoxifen administration and metabolism in nude mice and nude rats.

  2003cited by this paper
• Cisapride: A potential model substrate to assess cytochrome P4503A4 activity in vivo

  2003cited by this paper
• Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen.

  2002cited by this paper
• Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man

  2002cited by this paper
• Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites

  2002cited by this paper
• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

  2002cited by this paper
• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

  2002cited by this paper
• Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6.

  2002cited by this paper
• Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.

  2002cited by this paper
• Molecular and Pharmacokinetic Evaluation of Rat Hepatic and Gastrointestinal Cytochrome P450 Induction by Tamoxifen

  2001cited by this paper
• Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.

  2000cited by this paper
• Drug Interactions with Cisapride

  2000cited by this paper
• Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids.

  2000cited by this paper
• Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition

  2000cited by this paper
• Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy.

  2000cited by this paper
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women.

  1999cited by this paper
• National Cancer Institute-Common Toxicity Criteria

  1999cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Biologic activity of tamoxifen at low doses in healthy women.

  1998cited by this paper
• Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

  1998cited by this paper
• Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.

  1997cited by this paper
• CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.

  1997cited by this paper
• Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes.

  1997cited by this paper
• Age‐related difference in tamoxifen disposition

  1996cited by this paper
• Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

  1995cited by this paper
• Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer

  1993cited by this paper
• Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.

  1993cited by this paper
• Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.

  1992cited by this paper
• Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.

  1991cited by this paper
• Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.

  1990cited by this paper
• Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

  1989cited by this paper
• Tamoxifen metabolism: pharmacokinetic and in vitro study.

  1989cited by this paper
• Clinical pharmacokinetics : concepts and applications

  1989cited by this paper
• Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.

  1989cited by this paper
• Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile.

  1988cited by this paper
• Pharmacodynamic and biological effects of anti-estrogens in different models.

  1988cited by this paper
• Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography.

  1987cited by this paper
• Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.

  1987cited by this paper
• Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III.

  1987cited by this paper
• trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast.

  1986cited by this paper
• Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.

  1984cited by this paper
• A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

  1984cited by this paper
• Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.

  1984cited by this paper
• Non-Steroidal Antioestrogens

  1983cited by this paper
• Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.

  1982cited by this paper
• Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen.

  1982cited by this paper
• Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.

  1981cited by this paper
• Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.

  1980cited by this paper
• Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.

  1980cited by this paper

• Method-Comparison Validation of a Novel Capillary Blood Collection Kit, True Dose® TD-EPI, for Therapeutic Drug Monitoring of Epirubicin.

  2026cites this paper
• Rapamycin inhibits tamoxifen-induced endometrial proliferation in vitro as a pilot approach for endometrial protection in breast cancer

  2025cites this paper
• ESR1 and p53 interactome alteration defines mechanisms of tamoxifen response in luminal breast cancer

  2024cites this paper
• Weak base drug-induced endolysosome iron dyshomeostasis controls the generation of reactive oxygen species, mitochondrial depolarization, and cytotoxicity

  2024cites this paper
• Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules

  2024cites this paper
• Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?

  2024cites this paper
• EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancer

  2024cites this paper
• A Short Post-Reattachment Ultrasensitive Window of Time in Human Cancer Cells as Therapeutic Target of Prolonged Low-Dose Administration of Specific Compounds

  2024cites this paper
• Epithelial and mesenchymal phenotypes determine the dynamics of circulating breast tumor cells in microfluidic capillaries under chemotherapy-induced stress.

  2024cites this paper
• Creation of a point-of-care therapeutics sensor using protein engineering, electrochemical sensing and electronic integration

  2024cites this paper
• The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer

  2024cites this paper
• Behavioral and transcriptomic effects of the cancer treatment tamoxifen in mice

  2023cites this paper
• Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis

  2023cites this paper
• microRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells.

  2023cites this paper
• The immune activity of selective estrogen receptor modulators is gene and macrophage subtype-specific yet converges on Il1b downregulation.

  2023cites this paper
• Validation of a 3D perfused cell culture platform as a tool for humanised preclinical drug testing in breast cancer using established cell lines and patient-derived tissues

  2023cites this paper
• Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.

  2023cites this paper
• Upregulation of the EGFR/MEK1/MAPK1/2 signaling axis as a mechanism of resistance to antiestrogen-induced BimEL dependent apoptosis in ER+ breast cancer cells

  2022cites this paper
• Evaluation of human adipose-derived stromal cell behaviour following exposure to Tamoxifen.

  2022cites this paper
• Molecular Biomarker Expression in Window of Opportunity Studies for Oestrogen Receptor Positive Breast Cancer—A Systematic Review of the Literature

  2022cites this paper
• The tamoxifen-regulated, long non-coding RNA LINC00992 affects proliferation, migration, and expression of tamoxifen resistance-associated genes in MCF-7 breast cancer cells

  2022cites this paper
• Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction

  2022cites this paper
• Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells

  2022cites this paper
• Tamoxifen Twists Again: On and Off-Targets in Macrophages and Infections

  2022cites this paper
• The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa

  2022cites this paper
• Oestrogen Receptor Isoforms May Represent a Therapeutic Target in Oesophageal Adenocarcinoma

  2022cites this paper
• Bacteria modulate tamoxifen-induced death via host fatty acid metabolism 1 2

  2021cites this paper
• Tamoxifen: Will Less Equal More in Women with Precancerous Breast Disease?

  2021cites this paper
• Titratable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors

  2021cites this paper
• ERα-independent NRF2-mediated immunoregulatory activity of tamoxifen.

  2021cites this paper
• Bacterial diet modulates tamoxifen-induced death via host fatty acid metabolism

  2021cites this paper
• HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.

  2021cites this paper
• Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data

  2021cites this paper
• A tamoxifen receptor within a voltage-gated sodium channel

  2021cites this paper
• Autophagy Triggers Tamoxifen Resistance in Human Breast Cancer Cells by Preventing Drug-Induced Lysosomal Damage

  2021cites this paper
• Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients

  2021cites this paper
• Comprehensive understanding of multiple actions of anticancer drug tamoxifen in isolated mitochondria

  2021cites this paper
• Maternal obesity increases offspring’s mammary cancer recurrence and impairs tumor immune response

  2020cites this paper
• Soft Microenvironments Induce Chemoresistance by Increasing Autophagy Downstream of Integrin-Linked Kinase

  2020cites this paper
• Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation

  2020influential citation
• Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen

  2020cites this paper
• Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics

  2020cites this paper
• Polysaccharide Peptide Extract From Coriolus versicolor Increased Tmax of Tamoxifen and Maintained Biochemical Serum Parameters, With No Change in the Metabolism of Tamoxifen in the Rat

  2020cites this paper
• Tamoxifen is a candidate first‐in‐class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells—Unrecognized players in tumorigenesis

  2020cites this paper
• Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models

  2020cites this paper
• A unifying model to predict variable drug response for personalised medicine

  2020cites this paper
• Tamoxifen in the treatment of luminal breast cancer. Implications of active metabolites on gene expression, side effects and clinical outcome

  2019cites this paper
• Assessment of Drug-Induced Toxicity Biomarkers in the Brain Microphysiological System (MPS) Using Targeted and Untargeted Molecular Profiling

  2019cites this paper
• Protection from Endoplasmic Reticulum Stress and Apoptosis via PPARδ and Bcl-2 in Breast Cancer

  2019influential citation
• Mitochondrial fragmentation, elevated mitochondrial superoxide and respiratory supercomplexes disassembly is connected with the tamoxifen-resistant phenotype of breast cancer cells.

  2019cites this paper
• Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study

  2019cites this paper
• Effects of tamoxifen on periodontal disease and Candida albicans of patients with breast cancer and other pathologies.

  2019cites this paper
• Tamoxifen activity against Plasmodium in vitro and in mice

  2019cites this paper
• Low-dose Tamoxifen For Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

  2019cites this paper
• Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro.

  2019cites this paper
• Will a Low-Dose Option Improve Uptake of Tamoxifen for Breast Cancer Risk Reduction?

  2019cites this paper
• Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs

  2019cites this paper
• Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact

  2019cites this paper
• Modulation of Burst Firing of Neurons in Nucleus Reticularis of the Thalamus by GluN2C-Containing NMDA Receptors

  2019cites this paper
• Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial

  2018cites this paper
• Quality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women

  2018cites this paper
• The role of tamoxifen and some bioactive compounds in resistance to the development of toxicity causing breast cancer in experimental animals

  2018cites this paper
• Oxidative Stress and Neuronal Damages: Estrogenic Compounds, Anti-Apoptotic Factors, and Amyloidogenesis

  2018cites this paper
• Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance

  2018cites this paper
• Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy

  2018cites this paper
• CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy

  2018cites this paper
• Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice.

  2018cites this paper
• Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis

  2017cites this paper
• Therapeutic Drug Monitoring and Methods of Quantitation for Carbamazepine

  2017cites this paper
• The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes

  2017cites this paper
• Investigating barriers to tamoxifen adherence in women with breast cancer

  2017cites this paper
• Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats

  2017cites this paper
• Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis

  2017cites this paper
• Estrogen‐dependent modifications to hippocampal plasticity in paternal California mice (Peromyscus californicus)

  2017cites this paper
• In Vitro effects of tamoxifen on equine neutrophils.

  2017cites this paper
• Role of P‐glycoprotein inhibitors in ceramide‐based therapeutics for treatment of cancer

  2017cites this paper
• Response of patients with indolent systemic mastocytosis to tamoxifen citrate.

  2016cites this paper
• CYP2D6 inherited variation and inhibiting medication use in relation to adverse breast cancer outcomes after tamoxifen therapy

  2016cites this paper
• The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer

  2016cites this paper
• Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer

  2016cites this paper
• Developing peptide technologies to combat cancer and monogenetic disorders

  2016influential citation
• Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance

  2016cites this paper
• Tamoxifen citrate-loaded poly(d,l) lactic acid nanoparticles: Evaluation for their anticancer activity in vitro and in vivo

  2016cites this paper
• A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen

  2016cites this paper
• Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study

  2016cites this paper
• Exploration of individuality in drug metabolism by high-throughput metabolomics: The fast line for personalized medicine.

  2016cites this paper
• Deciphering the Nongenomic, Mitochondrial Toxicity of Tamoxifens As Determined by Cell Metabolism and Redox Activity.

  2016cites this paper
• Influence of Hydroalcoholic Vehicle on In Vitro Transport of 4-Hydroxy Tamoxifen Through the Mammary Papilla (Nipple)

  2016cites this paper
• Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells.

  2016cites this paper
• Tamoxifen as a new therapeutic tool for neutrophilic lung inflammation

  2016cites this paper
• PHARMGEONETIC EFFECT ON PLASMA CONCENTRATION OF TAMOXIFEN THROUGH HPLC IN FEMALE SUBJECTS OF PAKISTAN

  2016cites this paper
• The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells

  2015cites this paper
• Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.

  2015cites this paper
• Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.

  2015cites this paper
• Molecular imaging of estrogen receptors

  2015cites this paper
• Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants.

  2015cites this paper
• Regulation of lysophosphatidate-induced mechanisms of chemo-resistance

  2015cites this paper
• Tamoxifen metabolites can target both aromatase and estrogen receptors

  2015cites this paper
• Redox biology in normal cells and cancer: restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment.

  2015cites this paper
• CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

  2015cites this paper